drugset
drugset / Trial / NCT05196360

MAX-10181 in Patients With Advanced Solid Tumor

NCT05196360 ↗

Phase 1 Unknown 80 enrolled Maxinovel Pty., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This is a multi-center, open-label, single-arm, dose-escalation Phase I study to evaluate the safety and tolerability of MAX-10181 in patients with advanced solid tumor.

Timeline

Start
2021-08-11
Primary completion
2023-01-01
Completion
2023-05-01

Drugs

EvaluationDrugModalityDoseRoute
Subject MAX-10181 Small molecule — —

Indications

cancer